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Asthma-COPD overlap (ACO) is a term that encompasses patients with characteristics of
two conditions, smoking asthmatics or COPD patients with asthma-like features such as high
bronchodilator response or blood eosinophil count�300 cells/μL. The aim of this study was
to compare the different phenotypes inside the ACO definition in a real-life population cohort.
Methods
We analyzed patients from the MAJORICA cohort who had a diagnosis of asthma and/or
COPD based on current guidelines, laboratory data in 2014 and follow-up until 2015. Preva-
lence of ACO according to the different criteria, demographic, clinical and functional character-
istics, prescriptions and use of health resources data were compared between three groups.
Results
We included 603 patients. Prevalence of smoking asthmatics was 14%, COPD patients with
high bronchodilator response 1.5% and eosinophilic COPD patients 12%. Smoking asth-
matics were younger and used more rescue inhalers, corticosteroids and health resources.
Conversely, eosinophilic COPD patients were older than the other groups, often treated with
corticosteroids and had lower use of health resources. Most of the COPD patients with high
bronchodilator response were included in the eosinophilic COPD group.
Conclusions
ACO includes two conditions (smoking asthmatics and eosinophilic COPD patients) with
different medication requirement and prognosis that should not be pooled together. Use
of�300 blood eosinophils/μL as a treatable trait should be recommended.
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Introduction
The GOLD-GINA consensus recommends combining three characteristics of asthma and
three of chronic obstructive pulmonary disease (COPD) to make a diagnosis of overlap
between asthma and COPD (ACO). The assumption that patients with ACO are all similar,
irrespectively if the diagnosis comes from an asthma patient that smokes or from a COPD
patient with clinical characteristics of asthma, has led to consider ACO as an homogeneous
condition. However, recent studies have shown that ACO is actually an heterogeneous condi-
tion with clinical and inflammatory differences between smoking asthmatics and eosinophilic
COPD [1, 2].
A recent publication proposed an algorithm to help clinicians to identify ACO among
patients with chronic obstructive airway disease [3]. Firstly, it requires the diagnosis of COPD
based on current guidelines [4]. Secondly, the diagnosis of ACO can be considered in three dif-
ferent scenarios: 1) if the patient has also a previous diagnosis of asthma, or 2) if the patient
presents a high bronchodilator response (HBR, defined as a change of>400 ml and>15% in
FEV1) and/or 3) a significant blood eosinophil count (�300 cells/μL).
In view of these criteria, it is likely that an excessive importance is given to a HBR in order
to diagnose ACO. GOLD-GINA consensus recommends the use of 15% and 400 mL as cut-off
to define a HBR in ACO. However, there is evidence that up to 60% of patients with COPD
may demonstrate reversibility [5, 6] and that this is highly variable over time [7]. No broncho-
dilator test cut-off value has demonstrated to predict different clinical outcomes, neither in
asthma nor in COPD, and the prevalence of HBR in a population with chronic airflow obstruc-
tion or COPD is unknown. Thus, there is still no evidence that bronchodilator responsiveness
characterizes a disorder such as ACO.
Another potential marker for ACO diagnosis is a Th2 signature, expressed by the blood
eosinophil count as a surrogate marker of airway eosinophilia. Higher eosinophil counts
have been associated with increased risk of exacerbations and therapeutic responsiveness to
inhaled corticosteroids [8–11] in COPD patients. Nevertheless, whether asthmatics with
chronic obstruction or COPD patients with high eosinophil count have similar clinical
characteristics and response to inhaled corticosteroids (ICS) treatment has not been studied
yet.
The hypothesis of the present study is that ACO is a heterogeneous entity due to the combi-
nation of two different conditions with different underlying mechanisms, prognosis and thera-
peutic needs. The aim of the present study was to compare the prevalence, clinical
characteristics, lung function, laboratory data and prognosis of patients classified as ACO
from the three different approaches recommended by the aforementioned guidelines: co-diag-
nosis of asthma, HBR or eosinophil blood count�300 cells/μL.
Methods
Study design and ethics
This study used a retrospective design with prospective follow-up from a health-related popu-
lation database. The STROBE (Strengthening the Reporting of Observational Studies in Epide-
miology) recommendations were followed [6]. Individuals registered for primary care in the
Balearic Islands, Spain, during 2012 were included in the cohort that contains follow-up data
until 2015.
The study protocol was assessed and approved by the Balearic Primary Care Research Com-
mittee. Because of the retrospective design and use of anonymized data, this study was
exempted from ethics approval.
ACO is better identified by treatable traits
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Data source
Data were extracted from the Majorca Real-Life Investigation in COPD and Asthma (MAJOR-
ICA) cohort. The characteristics of this cohort have been described elsewhere [12]. Briefly, this
cohort contains combined data from three different data sources: primary care database, hos-
pital electronic charts and electronic prescription system in the Balearics, Spain. These three
data sources cover almost all clinical characteristics of, and health-care use by, the residents of
the Balearics islands (±1.1 million subjects). The MAJORICA cohort includes data from all
patients�18 years of age with a primary care diagnosis of asthma and/or COPD in 2012
(N = 68,578). All demographics, clinical data, laboratory tests, lung function, as well as
resource use and pharmacy dispense data for the period between 2012 and 2015 were
extracted.
Population
We included patients from the MAJORICA cohort who had (1)� 40 years of age; (2) smoking
exposure> 10 pack-years; (3) spirometry confirmed post-bronchodilator airflow obstruction
(FEV1/FVC< 0.7); (4) at least one eosinophil count in 2014; and (5) follow-up until 2015 (Fig 1).
ACO definitions
Following a recently published algorithm aimed to identify ACO [3], we divided the popula-
tion according the criteria fulfilled once the chronic airflow limitation and the tobacco expo-
sure were demonstrated. Sequentially and mutually exclusive, firstly, we identify patients with
a concomitant diagnosis of asthma and COPD (Smoking asthmatic, SA). Secondly, we distin-
guished patients with HBR, defined as bronchodilator response >400 ml and 15% in FEV1
(COPD-HBR). And thirdly, we discerned those patients with blood eosinophil count greater
than 300 cells/μL (COPD-Eo). Thus, all patients who had received a physician confirmed diag-
nosis of both asthma (International Classification of Diseases, 9th revision [ICD-9] code: 493)
and COPD (ICD-9 codes: 491, 492, and/or 496) in MAJORICA were identified as SA cases.
Subsequently, patients coded as COPD with HBR were classified as COPD-HBR cases; and
finally, other patients coded as COPD with a peripheral eosinophil count� 300 eosinophils/
μL in 2014 were classified as COPD-Eo cases. All other patients who did not meet any of these
criteria were classified as COPD cases (Fig 1).
Study size and data analysis
No formal sample size estimation was conducted because we were able to explore the entire
population domain.
For quantitative and normally distributed variables results are expressed as
mean ± standard deviation. If they are not normally distributed, results are presented with
median and [interquartile range] or with median and (range) when numbers where too small.
For categorical parameters, all groups are reported separately, using absolute number and per-
centage. ANOVA (or Kruskall-Wallis test) and unpaired t-tests (or Mann-Whitney U-tests)
were used to compare normally (and abnormally) distributed quantitative variables. Chi-
squared was used to compare categorical variables. Differences were considered statistically
significant at 2-tailed p<0.05.
Results
We included 603 patients who fulfilled all criteria, of which 165 were considered ACO accord-
ing to the aforementioned diagnostic algorithm. ACO patients were younger, relatively more
ACO is better identified by treatable traits
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often female, showed less cardiovascular comorbidities and more osteoporosis and rhinitis,
with more FEV1 reversibility, reduced rates of health resources use and more frequently
treated with ICS and short-acting beta agonists (SABA) compared to COPD without ACO cri-
teria (Table 1).
Fig 2 shows the prevalence of ACO according to the different definitions used. The overall
prevalence of ACO was 15 cases per 100,000 residents (� 18 years) of the Balearic Islands. SA
Fig 1. STROBE flow-chart. COPD: chronic obstructive pulmonary disease; BDT: bronchodilator test; FEV1: forced expiratory volume in the first
second; FVC: forced vital capacity; p/y: pack-years; SA: smoking asthmatic; Eos: eosinophil; ACO: asthma-COPD overlap; HBR: high bronchodilator
response.
https://doi.org/10.1371/journal.pone.0210915.g001
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prevalence was 13.8% (7.5 cases per 100,000 residents) and COPD-Eo prevalence was 12.1%
(6,6 cases per 100,000 residents). These results contrast with the very low prevalence of the
COPD-HBR group with only 1.5% (0.8 cases per 100,000 residents). The global prevalence of
ACO after applying the algorithm was 27.4% within a well-characterized COPD population.
Table 1. Demographic and clinical characteristics of COPD and ACO populations.
COPD (n = 438) ACO (n = 165) P-Value
Male 349 (79.7%) 108 (65.5%) <0.001
Age, years 67.66 ± 9.12 63.38 ± 9.62 <0.001
Pack-years 16.12 ± 18.89 18.40 ± 21.50 0.230
Comorbidities
Atrial Fibrillation 87 (19.9%) 14 (8.5%) 0.001
Anxiety, No. (%) 131 (29.9%) 58 (35.2%) 0.216
Osteoporosis 49 (11.2%) 29 (17.6%) 0.037
Allergic rhinitis 30 (6.8%) 21 (12.7%) 0.021
GERD, No. (%) 34 (7.8%) 16 (9.7%) 0.443
Nasal polyps, No. (%) 2 (0.5%) 3 (1.8%) 0.100
Treatment
SABA 195 (44.5%) 91 (55.2%) 0.020
LAMA 318 (72.6%) 108 (65.5%) 0.086
LAMA-LABA 62 (14.2%) 15 (9.1%) 0.097
ICS 21 (4.8%) 8 (4.8%) 0.978
LABA-ICS 232 (53.0%) 107 (64.8%) 0.009
OCS 156 (35.6%) 46 (27.9%) 0.073
Lung function
FVC postBD, liters 3.16 ± 0.91 3.28 ± 0.89 0.129
FVC postBD,% reference 85.50 ± 18.24 87.98 ± 16.83 0.117
FEV1 postBD, liters 1.65 ± 0.64 1.76 ± 0.61 0.048
FEV1 postBD,% reference 58.91 ± 19.34 61.85 ± 17.70 0.077
FEV1/FVC postBD 52.11 ± 12.70 53.61 ± 11.80 0.173
BDR <0.001
•Negative 370 (84.5%) 111 (67.3%)
•Positive (�200ml and�12%) 68 (15.5%) 38 (23.0%)
•Highly-positive (�400ml and�15%) 0 (0%) 16 (9.7%)
Eosinophils count
Mean Eos 0.15 ± 0.07 0.33 ± 0.21 <0.001
Median Eos 0.14 ± 0.08 0.32 ± 0.21 <0.001
Maximum Eos 0.27 ± 0.19 0.47 ± 0.38 <0.001
Use of health services
ED visits 1.74 ± 2.08 1.37 ± 1.95 0.040
Hosp all cause no. 1.14 ± 1.50 0.85 ± 1.50 0.036
Days of stay (all cause hosp) 9.60 ± 18.38 6.98 ± 19.28 0.133
Resp hosp no. 0.06 ± 0.28 0.10 ± 0.42 0.120
Days of stay (resp hosp) 0.40 ± 2.15 0.73 ± 3.55 0.167
P-Value (Chi-squared or T-student). Bolded text highlights variables with statistically significant differences (p�0.05). COPD: chronic obstructive pulmonary disease;
ACO: asthma-COPD overlap; SABA: short-acting beta agonists LABA: long-acting beta agonists; LAMA: long-acting muscarinic antagonists; ICS: inhaled
corticosteroids; OCS: oral corticosteroids (at least one prescription during the study period); FEV1: forced expiratory volume in 1st second; FVC: forced vital capacity;
postBD: post-bronchodilator; BDR: bronchodilator response; Eos: eosinophils; ED: emergency department; Hosp: hospitalization; Resp hosp: respiratory
hospitalization; No: number.
https://doi.org/10.1371/journal.pone.0210915.t001
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Although SA, COPD-HBR and COPD-Eo are diagnoses of exclusion, there can be some
patients who present more than one defining characteristic at the same time (Fig 3). We
observe that only a small proportion of patients with HBR are not included in the diagnoses of
SA or COPD-Eo. On the contrary, despite there is an overlap between the characteristics of SA
and COPD-Eo, these two populations present a significant and independent prevalence
reflecting two differentiated populations.
Comparison of the three ACO phenotypes
The demographic, clinical and functional characteristics of the three populations are shown in
Table 2. SA patients were younger, relatively more often female and more frequently diag-
nosed of allergic rhinitis. This group, despite being younger, having similar cigarette smoke
exposure and similar lung function used more SABA, ICS and oral corticosteroids (OCS) and
Fig 2. ACO prevalence. ACO: Asthma-COPD overlap; COPD: Chronic obstructive pulmonary disease; SA: smoking asthmatic; Eos: Eosinophil; HBR:
High bronchodilator response.
https://doi.org/10.1371/journal.pone.0210915.g002
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made a higher use of health services compared to COPD-HBR and COPD-Eo (Fig 4).
COPD-HBR patients were infrequent and shared almost all the characteristics with COPD-Eo
patients. COPD-Eo patients were more frequently males, older than the other groups, often
treated with corticosteroids, had higher eosinophil counts and lower rates of exacerbations.
Differential characteristics of smoking asthmatics (SA) and COPD with
asthma features (COPD-HBR+COPD-Eo) populations
As previously mentioned, SA patients were younger, relatively more often women and they
presented more asthma-related comorbidities (allergic rhinitis and GERD, Table 3).
SA patients showed greater use of SABA and corticosteroids (oral and inhaled). On the con-
trary, the COPD-HBR+COPD-Eo group used more long-acting muscarinic antagonists
Fig 3. Venn diagram representing the overlap of the three ACO phenotypes. The square represents the entire COPD population.
Patients who meet more than one definition of ACO are those who overlap with more than one circumference. COPD: Chronic
obstructive pulmonary disease; Eos: Eosinophil; ACO: Asthma-COPD overlap; HBR: High bronchodilator response.
https://doi.org/10.1371/journal.pone.0210915.g003
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Table 2. Demographic and clinical characteristics of the three ACO definitions.
SA (n = 83) COPD-HBR (n = 9) COPD-Eo (n = 73) P-Value
Male 47 (56.6%) 8 (88.9%) 53 (72.6%)§ 0.035
Age, years 61.00 [53.00–67.00] 65.00 [58.50–68.50]� 66.00 [60.00–72.50]§ 0.002
Pack-years 15.00 [4.00–21.00] 5.00 [2.00–39.00] 9.00 [3.00–26.50] 0.374
Comorbidities
Atrial Fibrillation 9 (10.8%) 1 (11.1%) 4 (5.5%) 0.467
Anxiety, No. (%) 35 (42.2%) 3 (33.3%) 20 (27.4%) 0.155
Osteoporosis 17 (20.5%) 0 (0%) 12 (16.4%) 0.291
Allergic rhinitis 16 (19.3%) 0 (0%) 5 (6.8%)§ 0.034
GERD, No. (%) 12 (14.5%) 0 (0%) 4 (5.5%) 0.100
Nasal polyps, No. (%) 3 (3.6%) 0 (0%) 0 (0%) 0.221
Treatment
SABA 59 (71.1%) 4 (44.4%) 28 (38.4%)§ <0.001
LAMA 48 (57.8%) 8 (88.9%) 52 (71.2%) 0.067
LAMA-LABA 4 (4.8%) 1 (11.1%) 10 (13.7%) 0.153
ICS 7 (8.4%) 0 (0%) 1 (1.4%) 0.096
LABA-ICS 71 (85.5%) 3 (33.3%)� 33 (45.2%)§ <0.001
OCS 35 (42.2%) 1 (11.1%) 10 (13.7%)§ <0.001
Lung function
FVC postBD, liters 3.23 [2.60–3.56] 3.77 [3.49–4.50]� 3.22 [2.72–3.81] ] 0.047
FVC postBD,% reference 88.70 [77.80–97.60] 89.80 [75.05–98.35] 87.60 [74.85–99.80] 0.965
FEV1 postBD, liters 1.71 [1.31–2.10] 2.07 [1.43–2.75] 1.74 [1.29–2.10] 0.249
FEV1 postBD,% reference 59.10 [47.80–74.70] 67.70 [50.70–74.60] 62.80 [49.35–76.10] 0.716
FEV1/FVC postBD 56.40 [43.80–63.10] 52.90 [46.60–61.70] 56.60 [46.60–63.90] 0.958
BDR <0.001
•Negative 54 (65.1%) 0 (0%)� 57 (78.1%)§ <0.001
•Positive (�200 ml and�12%) 22 (26.5%) 0 (0%)� 16 (21.9%) <0.001
•Highly-positive (�400ml and�15%) 7 (8.4%) 9 (100%)� 0 (0%)§ <0.001
Eosinophils count
Mean Eos 0.18 [0.10–0.29] 0.31 [0.23–0.43]� 0.37 [0.34–0.49]§ <0.001
Median Eos 0.15 [0.09–0.30] 0.29 [0.24–0.41]� 0.38 [0.33–0.48]§ <0.001
Maximum Eos 0.27 [0.17–0.40] 0.43 [0.27–0.75]� 0.49 [0.41–0.69]§ <0.001
Use of health services
ED visits 1.00 (0–12) 1.00 (0–7) 0 (0–6)§ 0.044
Hosp all cause no. 1.00 (0–13) 1.00 (0–4) 0 (0–3)§ 0.020
Days of stay (all cause hosp) 2.00 (0–205) 5.00 (0–28) 0 (0–37)§ 0.022
Resp hosp no. 0 (0–3) 0 (0–0) 0 (0–2)§ 0.093
Days of stay (resp hosp) 0 (0–35) 0 (0–0) 0 (0–9) 0.095
P-Value (Chi-squared or Kruskal-Wallis). Bolded text highlights variables with statistically significant differences (p�0.05).
�P-value <0.05 between SA and COPD-HBR;
§P-value <0.05 between SA and COPD-Eo;
]P-value < 0.05 between COPD-HBR and COPD-Eo. COPD: chronic obstructive pulmonary disease; ACO: asthma-COPD overlap; HBR: high bronchodilator response;
Eo: eosinophil; SABA: short-acting beta agonists LABA: long-acting beta agonists; LAMA: long-acting muscarinic antagonists; ICS: inhaled corticosteroids; OCS: oral
corticosteroids (at least one prescription during the study period); FEV1: forced expiratory volume in 1st second; FVC: forced vital capacity; postBD: post-
bronchodilator; BDR: bronchodilator response; ED: emergency department; Hosp: hospitalization; Resp hosp: respiratory hospitalization; No: number.
https://doi.org/10.1371/journal.pone.0210915.t002
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(LAMA). COPD-HBR+COPD-Eo presented a higher eosinophil count. Despite no differences
in lung function, the SA patients showed higher number of hospitalizations.
Differential characteristics between COPD (non-ACO) vs COPD with
asthma features (COPD-HBR+COPD-Eo) populations
When excluding the previous diagnosis of asthma, COPD patients with eosinophil
counts�300 (COPD-Eo) or HBR (COPD-HBR) were similar to COPD patients without these
criteria in terms of age, smoking history and baseline lung function. However, non-ACO
COPD patients presented more exacerbations, as defined by a higher use of OCS and health
services compared to COPD-HBR+COPD-Eo patients (S1 Table).
Comparison between COPD (non-ACO) vs smoking asthmatic (SA)
populations
SA patients were younger and relatively more frequently females, presented more asthma-
related comorbidities, reversibility and a higher use of SABA and ICS. The number of respira-
tory hospitalizations and hospital nights were increased in the SA group (S2 Table).
Fig 4. Use of health resources. COPD: Chronic obstructive pulmonary disease; ACO: Asthma-COPD overlap; No: number; ED: emergency department.
https://doi.org/10.1371/journal.pone.0210915.g004
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Discussion
In this study, we have validated a new proposed algorithm to differentiate a specific phenotype
of COPD in a population cohort. Using the aforementioned algorithm we identified that
Table 3. Demographic and clinical characteristics of smoker asthmatic (SA) and COPD with asthma features (COPD-HBR+COPD-Eo) populations.
SA (n = 83) COPD-HBR+COPD-Eo (n = 82) P-Value
Male 47 (56.6%) 61 (74.4%) 0.016
Age, years 60.98 ± 9.67 65.82 ± 8.99 0.001
Pack-years 20.29 ± 23.61 16.5 ± 19.08 0.259
Comorbidities
Atrial Fibrillation 9 (10.8%) 5 (6.1%) 0.274
Anxiety, No. (%) 35 (42.2%) 23 (28%) 0.058
Osteoporosis 17 (20.5%) 12 (14.6%) 0.324
Allergic rhinitis 16 (19.3%) 5 (6.1%) 0.011
GERD, No. (%) 12 (14.5%) 4 (4.9%) 0.038
Nasal polyps, No. (%) 3 (3.6%) 0 (0%) 0.082
Treatment
SABA 59 (71.1%) 32 (39.0%) <0.001
LAMA 48 (57.8%) 60 (73.2%) 0.038
LAMA-LABA 4 (4.8%) 11 (13.4%) 0.055
ICS 7 (8.4%) 1 (1.2%) 0.031
LABA-ICS 71 (85.5%) 36 (43.9%) <0.001
OCS 35 (42.2%) 11 (13.4%) <0.001
Lung function
FVC postBD, liters 3.21 ± 0.8 3.36 ± 0.98 0.279
FVC postBD,% reference 87.44 ± 14.52 88.52 ± 18.95 0.683
FEV1 postBD, liters 1.71 ± 0.59 1.81 ± 0.62 0.253
FEV1 postBD,% reference 60.63 ± 17.96 63.08 ± 17.47 0.375
FEV1/FVC postBD 53.08 ± 12.8 54.15 ± 10.74 0.562
BDR 0.529
•Negative 54 (65.1%) 57 (69.5%) 0.512
•Positive (�200ml and�12%) 22 (26.5%) 16 (19.5%) 0.542
•Highly-positive (�400ml and�15%) 7 (8.4%) 9 (11.0%) 0.581
Eosinophils count
Mean Eos 0.23 ± 0.22 0.43 ± 0.16 <0.001
Median Eos 0.22 ± 0.22 0.41 ± 0.15 <0.001
Maximum Eos 0.33 ± 0.26 0.61 ± 0.42 <0.001
Use of health services
ED visits 1.78 ± 2.29 0.95 ± 1.43 0.006
Hosp all cause no. 1.18 ± 1.89 0.52 ± 0.84 0.004
Days of stay (all cause hosp) 10.33 ± 25.92 3.59 ± 7.02 0.024
Resp hosp no. 0.17 ± 0.54 0.04 ± 0.25 0.044
Days of stay (resp hosp) 1.24 ± 4.77 0.22 ± 1.4 0.064
P-Value (Chi-squared or T-student). Bolded text highlights variables with statistically significant differences (p�0.05). COPD: chronic obstructive pulmonary disease;
ACO: asthma-COPD overlap; HBR: high bronchodilator response; Eo: eosinophil; SABA: short-acting beta agonists LABA: long-acting beta agonists; LAMA: long-
acting muscarinic antagonists; ICS: inhaled corticosteroids; OCS: oral corticosteroids (at least one prescription during the study period); FEV1: forced expiratory
volume in 1st second; FVC: forced vital capacity; postBD: post-bronchodilator; BDR: bronchodilator response; ED: emergency department; Hosp: hospitalization; Resp
hosp: respiratory hospitalization; No: number.
https://doi.org/10.1371/journal.pone.0210915.t003
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27.4% of all COPD patients fulfilled the definition of ACO, and these patients were more fre-
quently treated with ICS and showed a better prognosis in terms of healthcare utilization
(emergency visits and all-cause hospitalizations). Moreover, we have addressed the heteroge-
neity of this group of patients classified under the umbrella of ACO, and differentiate eosino-
philic COPD from those patients with COPD with a previous diagnosis of asthma as different
entities with different clinical characteristics and prognosis in terms of hospital admissions
and visits to emergency department. This findings remark a change of perspective when
approaching this topic. Maybe, is time to abandon the search of phenotypes and to start find-
ing treatable traits and specific biomarkers, to guide clinicians to customize the treatment of
the patients.
Previous studies
The need for a definition to adequately identify those patients who have features of COPD and
asthma has been a reality and a topic of debate in recent years [13, 14]. However, the first stud-
ies that were conducted to study the overlap of Asthma and COPD, already noticed the hetero-
geneity of this entity [15]. Therefore, diagnostic approaches based on the study of
inflammatory patterns in patients with COPD, asthma and patients with ACO have been pro-
posed [16].
Some authors have used blood eosinophils and HBR as criteria to identify ACO patients
[17, 18]. Sin et al proposed a consensus definition for ACO with four major and three minor
criteria [18]. HBR was proposed as a major criterion if no history of asthma before 40 years
was documented, and blood eosinophil count was considered a minor criterion.
The major differences in the definition of ACO used across the studies have led to incon-
gruent data regarding its prevalence. Despite this, when the diagnosis of ACO is made in adults
with COPD and previous diagnosis of asthma (SA), the prevalence varies between 13% and
18% [12, 19, 20]. In a recent study that applied the same proposed algorithm in a population of
patients with chronic airflow limitation the prevalence was 29.8% [21]. These data would agree
with the SA prevalence (13.8%) and with the total prevalence of ACO (27.4%) found in this
cohort.
Regarding the evidence that currently exists on ACO prognosis, contradictory data are
found, probably also related to different definitions used. When comparing COPD and ACO
patients (defined by previous asthma diagnosis and/or asthma-like features), ACO patients
showed better prognosis in terms of survival [20], lung function and exacerbations, even after
10-years of follow-up [22]. These findings are consistent with the Casanova et al results, in
which the impact of persistent blood eosinophilia on exacerbations and survival was studied in
COPD patients and smoking controls [23]. Despite not finding differences in the rate of exac-
erbations, mortality was lower in patients with blood eosinophil count� 300 cells/μL com-
pared to those with lower values [23]. On the contrary, Turato et al found no relationship
between blood eosinophil levels and the rate of exacerbations or mortality in both, COPD
patients or smoking controls. Of note, 61% of COPD patients were receiving ICS despite being
predominantly of mild to moderate severity, which likely might contribute to equalize differ-
ences with non-Eosinophilic COPD [24].
The heterogeneity within ACO has already been explored [1, 25]. Pe´rez-de-Llano et al stud-
ied clinical and inflammatory profile differences between smoking asthmatics with airflow
obstruction (SA) and eosinophilic inflammation COPD patients (COPD-Eo) [1]. They found
that smoking asthmatics were more often females and had more atopic features. However,
Th2-related biomarkers (periostin and FeNO) were higher in eosinophilic COPD patients.
This heterogeneity could explain why other authors describe ACO patients as subjects with
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worse prognosis in relation to COPD patients. Hardin and colleagues compared subjects with
both COPD and asthma (SA) with COPD alone [19]. They found ACO patients had worse
health-related quality of life and experienced more exacerbations despite younger age. These
results are consistent with our results where the SA group showed higher number of hospitali-
zations compared to the COPD-HBR+COPD-Eo group and COPD (non-ACO) group.
Interpretation of results
The global prevalence of ACO, 27.4% is not negligible. Therefore, the effort of the scientific
community to try to understand this condition is reasonable. Nevertheless, the criteria of HBR
(COPD-HBR) had a very low prevalence (1.5%) and more than 50% of these patients had
blood eosinophil levels higher than 300 cells/μL. These factors suggest that this entity is not
clinically relevant. Most of these patients would be included in COPD-Eo group.
We have shown that ACO is an umbrella term that includes two conditions with different
clinical characteristics and prognosis. The common belief that ACO confers poorer prognosis
[19] comes from the patients that we have considered as SA, which are smoking asthmatics.
However, ACO patients with HBR or mainly high eosinophil counts without asthma
(COPD-HBR+COPD-Eo) present better prognosis than COPD without ACO and COPD with
asthma (SA). A possible explanation about the better prognosis of COPD-HBR+COPD-Eo
could be the use of inhaled corticosteroids, which is over 50% in these patients.
On the other hand, just 20.5% of SA patients present an eosinophil count�300 cells/μL.
Therefore, a proportion of this population is likely to have a neutrophilic asthma phenotype,
which is currently known to respond poorly to corticosteroids. This characteristic would jus-
tify the poorer prognosis of the SA group despite being younger with no differences in lung
function compared with the COPD non-ACO and COPD-HBR+COPD-Eo groups.
Clinical implications
One objective of defining new phenotypes in COPD is to find the most suitable treatment for
each one. The GOLD-GINA consensus recommends the use of ICS in patients with ACO.
Therefore, regarding to ICS treatment recommendation, the proposed algorithm is valid
mainly for the COPD-Eo group, since the COPD-HBR is not clinically relevant and the SA
may benefit from other future biological therapies.
Limitations
Our study has several limitations. First, this is a retrospective cohort study and therefore we
were not able to address how COPD and asthma interact to modify the prognosis. Second,
there is no gold standard for the diagnosis of asthma in a COPD population. Third, the cut-off
eosinophil point to define COPD-Eo is arbitrary; a threshold of 300 eosinophils/μL was chosen
following previous studies [3, 21, 23]. Fourth, our patients were recruited from public health
services with universal health care and they were receiving treatment for COPD according to
clinical practice; this could affect the results of the clinical outcomes like blood eosinophils or
exacerbations. Results are not directly generalizable to patients coming from asthma clinics.
Finally, 1-year follow-up might be too short to register COPD exacerbations.
Conclusions
ACO is a prevalent and heterogeneous disorder that generates confusion because includes
patients with different pathophysiology and prognosis, namely smoking asthmatics and eosin-
ophilic COPD. This important heterogeneity leads us to think that probably using the term
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ACO to define all these patients can be confusing. From the practical point of view, the eosino-
philic COPD (COPD-Eo group) identifies those COPD patients that would benefit the most
from ICS. Moreover, the role of HBR is negligible and should not be used to identify this con-
dition. We propose to abandon this term, and modify treatment of COPD by using a treatable
trait such as the Th2 signature, using the blood eosinophil count as a marker. We should inves-
tigate now what is the best eosinophil cut-off point to predict the effective response to ICS.
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